Inhibition of p22 phox Suppresses Epithelial Ovarian Cancer Cell Proliferation and Tumorigenesis

Qi Li,Xiaomin Feng,Fengnan Niu,Jun Yang,Yuemei Xu,Xiaohong Pu,Jun Chen,Xiangshan Fan,Binghua Jiang,Qin Huang
DOI: https://doi.org/10.7150/jca.54163
IF: 3.9
2021-01-01
Journal of Cancer
Abstract:The aim of this study was to investigate the biological role and molecular mechanism of p22<sup>phox</sup> in epithelial ovarian cancer. Immunohistochemistry was employed to determine the p22<sup>phox</sup> expression level in epithelial ovarian cancer tissues. The effects of p22<sup>phox</sup> on epithelial ovarian cancer cell proliferation, tumorigenesis, and chemosensitivity were evaluated by CCK-8, EdU assay, colony formation and apoptosis assays in vitro and by mouse experiments in vivo. Immunoprecipitation analyses were utilized to explore the potential mechanisms of p22<sup>phox</sup> mediated downstream signaling, and RT-PCR and western blot were used to confirm the relevance. P22<sup>phox</sup> expression could be detected in epithelial ovarian cancer tissues and normal fallopian epithelial cells. Silencing p22<sup>phox</sup> suppressed epithelial ovarian cancer cell proliferation and colony formation capacity <i>in vitro</i>, and inhibited the tumor growth in nude mice bearing the A2780 xenograft <i>in vivo</i>. Mechanistic investigations showed that p22<sup>phox</sup> regulated proteasome ubiquitination and subsequent proteasome-dependent degradation of p53 in A2780 and U87 cells <i>in vitro</i>. Furthermore, knockdown of p22<sup>phox</sup> significantly increased the chemosensitivity of A2780 cells to cisplatin or paclitaxel. These results suggested that p22<sup>phox</sup> as a pivotal oncogene during epithelial ovarian cancer carcinogenesis and p22<sup>phox</sup> inhibition might be a potential therapeutic strategy for epithelial ovarian cancer.
oncology
What problem does this paper attempt to address?